Fate Therapeutics
FATE
₹101.88
Share price
-10.00%
Change (1 day)
-77.51%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : ₹9.60 Billion
According to Fate Therapeutics 's latest financial reports the company's total liabilities are ₹9.60 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Fate Therapeutics - Total liabilities on balance sheet (from 2012 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | ₹10.46 B | -8.79% |
| 2023-12-31 | ₹11.47 B | -37.45% |
| 2022-12-31 | ₹18.33 B | 1.56% |
| 2021-12-31 | ₹18.05 B | 3.74% |
| 2020-12-31 | ₹17.40 B | 324.38% |
| 2019-12-31 | ₹4.10 B | 11.6% |
| 2018-12-31 | ₹3.67 B | 104.82% |
| 2017-12-31 | ₹1.79 B | 20.61% |
| 2016-12-31 | ₹1.48 B | -25.17% |
| 2015-12-31 | ₹1.98 B | 37.34% |
| 2014-12-31 | ₹1.44 B | 394.91% |
| 2013-12-31 | ₹0.29 B | -91.64% |
| 2012-12-31 | ₹3.49 B | 12.99% |
| 2011-12-31 | ₹3.09 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | ₹202.25 B | 2,006.51% | 🇺🇸 USA |
 Becton Dickinson BDX | ₹2.545 T | 26,406.20% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | ₹247.40 B | 2,476.75% | 🇺🇸 USA |
 Avidity Biosciences RNA | ₹11.35 B | 18.22% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | ₹100.31 B | 944.79% | 🇺🇸 USA |